BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34281526)

  • 1. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
    Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
    BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
    Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
    Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of
    Sugimoto Y; Katsumi Y; Iehara T; Kaneda D; Tomoyasu C; Ouchi K; Yoshida H; Miyachi M; Yagyu S; Kikuchi K; Tsuchiya K; Kuwahara Y; Sakai T; Hosoi H
    Mol Cancer Ther; 2020 Oct; 19(10):1992-2000. PubMed ID: 32847975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma.
    Lu X; Liu M; Yang J; Que Y; Zhang X
    Clin Exp Immunol; 2022 Aug; 209(2):127-139. PubMed ID: 35867577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
    Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
    Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1.
    Saitoh Y; Bureta C; Sasaki H; Nagano S; Maeda S; Furukawa T; Taniguchi N; Setoguchi T
    Mol Carcinog; 2019 Feb; 58(2):234-246. PubMed ID: 30303565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
    Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y
    Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
    Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Iwasaki H; Sonobe H; Goto H; Kusakabe H; Takahira T; Kobayashi C; Kawaguchi K; Saito T; Yamamoto H; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2006 Jun; 19(6):820-31. PubMed ID: 16557275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
    Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
    BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor.
    Nakano Y; Takadera M; Miyazaki M; Qiao Z; Nakajima K; Noguchi R; Oyama R; Kimura Y; Okuhiro Y; Yamasaki K; Kunihiro N; Fukushima H; Inoue T; Hara J; Ozawa T; Kondo T; Ichimura K
    Hum Cell; 2021 Jan; 34(1):271-278. PubMed ID: 32997328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway.
    Zheng J; Lu Y; Xiao J; Duan Y; Zong S; Chen X; Hu T; Li L; Zhang Y
    Int Immunopharmacol; 2023 Mar; 116():109753. PubMed ID: 36738675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
    BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdoid tumor growth is inhibited by flavopiridol.
    Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
    Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
    Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors.
    Muscat A; Popovski D; Jayasekara WS; Rossello FJ; Ferguson M; Marini KD; Alamgeer M; Algar EM; Downie P; Watkins DN; Cain JE; Ashley DM
    Clin Cancer Res; 2016 Jul; 22(14):3560-70. PubMed ID: 26920892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.